Please assess the completion status of the following clinical trial:

Trial Title: Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females without child bearing potential aged 21-80 years~* Fasting low-density lipoprotein (LDL) level \> 120mg/dL.~* Either known to be diabetic or have at least 3 components of metabolic syndrome that are defined below:~  * Hypertension defined as blood pressure (BP) \> 140 systolic or \> 90 mmHg diastolic, or stable medical therapy for documented hypertension;~ * Fasting glucose \> 110 mg/dL;~ * Waist \> 40 inches in males, and \> 35 inches in females;~ * Triglycerides \> 150mg/dL; or~ * High-density lipoprotein (HDL) cholesterol \< 40 mg/dL in males and \< 50 mg/dL in females.~* Able to provide written informed consent~* Non-smoker~Exclusion Criteria:~* On any oral antioxidants or lipid lowering medications in the previous 8 weeks~* Age \< 21 or \> 80 years~* Premenopausal females with potential for pregnancy~* LDL cholesterol level \< 120 mg/dl~* Initiation or change in dose of any concomitant medical therapy within 2 months before the study~* Uncontrolled hypertension with BP \> 180 mmHg systolic and \> 120 mmHg diastolic~* Current smoker~* Previous intolerance or allergy to statins~* Acute infection in previous 4 weeks~* History of substance abuse~* Uninterpretable Brachial Artery Reactivity Study~* Current neoplasm~* Chronic renal failure (creatinine \> 2.5 mg/dL) or liver failure (liver enzymes \> 2X normal)~* Acute coronary syndrome, heart failure, cerebrovascular accident (CVA), or coronary intervention within 3 months~* Known aortic stenosis, hypertrophic cardiomyopathy, or symptomatic heart failure.~* Inability to give informed consent~* Inability to return to Emory for follow-up

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin 10MG (Type: EXPERIMENTAL): None
- Pravastatin 80mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).